ENVB — Enveric Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 890821 ·
Last close
$1.35
Market Cap
$5.44M
52W High
$7.88
52W Low
$1.26
ADV30
180,941
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,633,170 | -1,633,473 | 5,521,464 | 4,908,769 | 460,676 |
| Dec 2025 | 0 | — | -2,193,923 | -2,194,171 | 5,095,941 | 4,677,491 | 918,400 |
| Sep 2025 | 0 | — | -1,873,943 | -1,873,669 | 4,362,061 | 3,757,594 | 905,885 |
| Jun 2025 | 0 | — | -2,519,049 | -2,519,181 | 3,548,454 | 2,849,816 | 1,363,685 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,006,800
Investing CF
$0
Financing CF
$8,633,801
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-27.44
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-116,479,965
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-8,220,085
Pretax Income TTM
$-8,220,494
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,774,448 | -8,771,987 | 5,095,941 | 918,400 | — | -8,141,543 |
| Dec 2024 | 0 | -9,632,266 | -9,574,987 | 3,082,543 | 1,489,736 | — | -7,726,139 |
| Dec 2023 | 0 | -18,296,675 | -17,310,773 | 4,299,840 | 2,343,504 | — | -14,094,411 |
| Dec 2022 | 0 | -19,961,444 | -18,504,347 | 19,552,925 | 3,995,973 | — | -17,146,723 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DRMA | Dermata Therapeutics, Inc. | $5.39M | $1.34 | — |
| SNGX | SOLIGENIX, INC. | $5.34M | $0.36 | — |
| NCNA | NuCana plc | $5.58M | $1.34 | — |
| NXTS | Nexentis Technologies Inc. | $5.29M | $3.64 | — |
| GELS | Gelteq Ltd | $5.62M | $0.52 | — |
News headlines (Yahoo Finance, 1h cache)
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
2026-06-29 12:00 · Yahoo
Enveric Biosciences Announces Participation in 2026 BIO International Convention
2026-06-16 13:28 · Yahoo
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
2026-06-09 12:00 · Yahoo
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
2026-06-02 12:00 · Yahoo
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
2026-04-28 11:33 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-02-23 00:43 · Yahoo
Enveric Biosciences reports EB-003 receptor engagement assay data
2026-02-20 13:09 · Yahoo
Enveric Biosciences announces issuance of U.S. patent
2025-12-30 13:10 · Yahoo
AbbVie's Bretisilocin Hit With Enveric IP Claim
2025-10-15 18:48 · Yahoo
Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal
2025-10-15 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.